Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - September 29, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
By: Nasdaq / GlobeNewswire - 23 Nov 2017 | Back to overview list |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Message from the CEO IBT announced results from the safety and tolerability study of IBP-9414 on September 11 th . The data demonstrate a similar safety and tolerability profile in the active and placebo groups. The study included 120 preterm infants, dosed during two weeks and evaluated at time points up to 6 months after administration of the study drug at 15 neonatal centers in the United States. We can conclude that the recruitment rate was higher than expected without any variance between large or small infants and that the demographics of the study population was representative of the target population. IBT was able to complete the study according to plan in terms of recruitment, timelines and budget. We are continuing our preparations for the next and final part of the IBP-9414 development program, the planned pivotal efficacy study for the prevention of NEC. In September, The Paediatric Committee (PDCO) at the European Medicines Agency (EMA) adopted a positive opinion on the "Paediatric Investigation Plan" proposed by IBT for the development of IBP-9414 for the prevention of necrotizing enterocolitis (NEC). Adoption of the "Paediatric Investigation Plan" is a prerequisite for continuing our clinical development program. I am very happy that the IBT team again has shown its capability to reach a significant milestone in the global development program. IBT has the financial resources to prepare the following pivotal study of IBP-9414 which is planned to be initiated in the beginning of 2018. The ongoing planning and preparations for the pivotal study include CMC (Chemical, manufacturing and control) activities for the production of clinical trial material. As previously announced, the pivotal study will require additional capital. IBT is working very actively on several different financing possibilities. In addition, IBT is progressing in its preparation for the application to admittance for trading on the main marketplace, Nasdaq Stockholm as previously communicated.
Staffan Strömberg
Significant events during the third quarter 2017
Significant events during the reporting period January - September 2017
Significant events after the reporting period
Infant Bacterial Therapeutics AB (publ) Interim Report is now available on the company's website www.ibtherapeutics.com .
About Infant Bacterial Therapeutics AB
IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.
IBT is listed on Nasdaq First North Premier with Erik Penser Bank as Certified Adviser.
For additional information please contact
Publication
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Infant Bacterial Therapeutics AB via GlobeNewswire
HUG#2151456
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright 2017 Nasdaq / GlobeNewswire | Back to overview list |